CAR-T Therapy for Autoimmune Disease in China: What's Actually Happening

What This Article Covers

Chimeric antigen receptor T-cell (CAR-T) therapy, built and approved as a cancer treatment, is now being tested against a very different target: severe, treatment-resistant autoimmune disease, especially lupus. China has emerged as the single busiest country in the world for this research, running roughly half of all registered CAR-T-for-autoimmune-disease trials globally. This article covers what that activity actually consists of, what the early published data shows, and why — despite genuinely exciting signals — no CAR-T product is approved for an autoimmune indication anywhere on Earth, including China.

Why China Is the Center of Gravity for This Research

Several converging factors explain why China dominates this space. First, the country already built substantial CAR-T manufacturing and clinical infrastructure for oncology: its drug regulator, the National Medical Products Administration (NMPA), approved its first cancer CAR-T product in 2021 (relmacabtagene autoleucel, for lymphoma), and several more have followed for lymphoma and myeloma. That existing pipeline — cell-processing facilities, trained clinical teams, and regulatory familiarity with the modality — made it comparatively easy for biotech companies and academic hospitals to pivot the same technology toward autoimmune disease.

Second, China has a very large population of patients with refractory systemic lupus erythematosus (SLE) and lupus nephritis who have exhausted standard immunosuppressive options, giving investigators a substantial recruitment base for early-phase trials. Industry analysts at GlobalData have specifically flagged China as an "emerging key player" in CAR-T for SLE and lupus nephritis assets, alongside the United States and Germany (where the modality was first piloted in autoimmune disease).

Third, a cluster of Chinese biotech firms and university hospitals — including Gracell Biotechnologies and teams at institutions such as Tongji Hospital, affiliated with Huazhong University of Science and Technology — have specifically prioritized autoimmune indications as a next frontier after oncology, rather than treating it as a side project.

The Trial Landscape, by the Numbers

A 2025 brief report in Frontiers in Immunology that systematically reviewed the global clinical trial registry found:

• 56 total registered trials of CAR-T (and related cellular) therapy for autoimmune rheumatic disease worldwide as of May 2025.
• China accounted for 27 of those 56 trials (48%); the United States accounted for 19 (34%). Only two trials involved sites in both countries.
• The field is overwhelmingly early-stage: 64% of trials are Phase I, and only about 7% have reached Phase II. No trial has reached Phase III.
• Most trials (91%) were still open/recruiting at the time of the review.
• Funding comes mostly from smaller biotech companies (75%) and academic institutions (17%); only 8% of trials are backed by major pharmaceutical companies — reportedly because oncology remains far more commercially attractive than the comparatively small autoimmune-disease patient population targeted here.

Concretely, Chinese trial registrations include multiple CD19-, BCMA-, and dual CD19/BCMA-targeted CAR-T studies for refractory SLE and lupus nephritis (including pediatric lupus nephritis), as well as newer constructs targeting CD70. Gracell's GC012F product received NMPA clearance for a Phase 1/2 trial in refractory SLE, and several hospital-sponsored studies are independently registered on international trial databases.

What the Evidence Actually Shows

The most notable published result so far comes from Tongji Hospital researchers, who reported in Annals of the Rheumatic Diseases (July 2025) that a BCMA-targeted CAR-T therapy induced disease remission in patients with refractory lupus nephritis — a notoriously hard-to-treat kidney complication of lupus that often fails conventional immunosuppression. This kind of signal, echoing smaller pioneering case series out of Germany in 2021–2022, is genuinely encouraging: it suggests that depleting the autoreactive B-cell populations driving lupus with a single CAR-T infusion may achieve deep, sustained remission in some patients who have run out of other options.

That said, the evidence base remains preliminary by design. These are small, early-phase, often single-arm or single-center studies, frequently reported as case series or conference abstracts rather than large randomized trials. Follow-up periods are still short relative to a chronic, relapsing disease like lupus, so durability beyond one to two years is not yet established. And CAR-T carries real, well-documented risks carried over from its oncology use — cytokine release syndrome and neurotoxicity in the acute setting, plus a longer-term safety signal that regulators are watching closely: reports of secondary T-cell malignancies following CD19- and BCMA-directed autologous CAR-T products led global regulators to add safety warnings to these products in recent years, a signal relevant to any new application of the same cell platforms.

The Regulatory Picture: Trials Only, Not Treatments

This is the single most important fact for anyone researching this topic: no CAR-T product is approved as a drug for any autoimmune disease indication anywhere in the world — not in China, not in the United States, not in Germany. Every instance of CAR-T for lupus, lupus nephritis, or related autoimmune conditions in China today exists strictly within a registered clinical trial or an NMPA-cleared Investigational New Drug (IND) program. China's NMPA has cleared IND applications for several such trials, which is a meaningful regulatory step, but an IND clearance authorizes testing — it is not a marketing approval, and it carries no claim that the therapy is safe or effective for general use.

What This Means for Patients Considering It

Because these therapies are confined to formal trials, access is tightly controlled: eligible patients are typically those with severe, treatment-refractory disease who enroll through an academic hospital's trial program, not through a commercial clinic. Anyone encountering marketing for "CAR-T for lupus" or "CAR-T for autoimmune disease" outside of a registered trial with a clear protocol, informed-consent process, and institutional review should treat that as a red flag rather than an opportunity — this is not a modality with an established wellness or elective-treatment pathway, and it carries serious acute risks that require inpatient monitoring. Prospective participants should verify a trial's registration status directly (for example, on ClinicalTrials.gov or China's own trial registry), confirm it is sponsored by a recognized hospital or biotech sponsor, and discuss risks thoroughly with an independent specialist before considering enrollment, including via medical travel.

Bottom Line

China has become the world's most active country for CAR-T-in-autoimmune-disease research, running roughly half of all registered trials globally and producing some of the field's most encouraging early published results, including remission signals in refractory lupus nephritis. That is a genuinely positive and fast-moving story. But it is a trials-only story: no regulator anywhere has approved CAR-T for an autoimmune indication, the data are still early-phase and short-term, and the therapy carries real procedural and longer-term safety risks. For now, the accurate framing is "promising experimental research," not "available treatment."